<DOC>
	<DOC>NCT00174837</DOC>
	<brief_summary>The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.</brief_summary>
	<brief_title>TRACE: Tirapazamine-Radiation And Cisplatin Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Previously untreated squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx. Stage III or IV disease (excluding T1N1, and T2N1 and metastatic disease). Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. Absolute neutrophil count at least 1.5 X 10^9/L, platelet count at least 100 X 10^9/L, and hemoglobin &gt; 9g/dL. Serum bilirubin &lt; 1.25 times upper limit of normal (ULN) and aspartate aminotransferase (AST)/alanine transaminase (ALT) &lt; 2.5 times ULN. Calculated creatinine clearance (CockcroftGault) &gt; 55 mL/min. Metastatic Disease Primary cancers of the nasal and paranasal cavities and of the nasopharynx Significant intercurrent illness that will interfere with the Chemotherapy or Radiation Therapy during the trial Symptomatic peripheral neuropathy &gt; grade 2 Clinically significant hearing impairment Significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Tirapazamine</keyword>
	<keyword>Head and Neck Cancer</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Radiation</keyword>
</DOC>